Asthika Goonewardene
Stock Analyst at Truist Securities
(2.11)
# 2,945
Out of 5,152 analysts
89
Total ratings
41.86%
Success rate
-5.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Hold | $134 → $120 | $114.36 | +4.93% | 6 | Feb 24, 2026 | |
| ZYME Zymeworks | Initiates: Buy | $40 | $24.80 | +61.29% | 1 | Dec 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $25.25 | +70.30% | 1 | Nov 25, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $27.48 | +74.67% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $145.14 | -0.10% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $22.21 | +75.60% | 2 | Oct 7, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $13.97 | +615.82% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $99.64 | -0.64% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $41.28 | +18.70% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $101.95 | +52.04% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $71 | $17.75 | +300.00% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $2.31 | +332.90% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.49 | +573.40% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $4.58 | +227.51% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $14.94 | +134.27% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $22.50 | +566.67% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.05 | +95.12% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.71 | +1,011.11% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $432 | $7.46 | +5,690.88% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $8.53 | +1,306.80% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.20 | +4,900.00% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $12.76 | +1,310.66% | 4 | Aug 23, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $134 → $120
Current: $114.36
Upside: +4.93%
Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $24.80
Upside: +61.29%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $25.25
Upside: +70.30%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $27.48
Upside: +74.67%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $145.14
Upside: -0.10%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $22.21
Upside: +75.60%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $13.97
Upside: +615.82%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $99.64
Upside: -0.64%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $41.28
Upside: +18.70%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $101.95
Upside: +52.04%
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $17.75
Upside: +300.00%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $2.31
Upside: +332.90%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.49
Upside: +573.40%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $4.58
Upside: +227.51%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $14.94
Upside: +134.27%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $22.50
Upside: +566.67%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $2.05
Upside: +95.12%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.71
Upside: +1,011.11%
Sep 6, 2023
Reiterates: Buy
Price Target: $432
Current: $7.46
Upside: +5,690.88%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $8.53
Upside: +1,306.80%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.20
Upside: +4,900.00%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $12.76
Upside: +1,310.66%